JAK1 and rheumatoid arthritis: WXFL10203614, the potential selective JAK1 inhibitor, was well-tolerated and safe in healthy Chinese subjects, and plasma exposure increased in a dose-related manner after single-dose and once-daily administration, supporting further evaluation of WXFL10203614 in patients with RA.